S
Sepax-tech
Better Surface Chemistry for Better Separation
About Sepax-tech
Sepax Technologies, Inc. is a specialized company that operates in the biotechnology market, providing high-tech solutions for the separation and analysis of biomolecules. Their products are primarily used in the pharmaceutical and biotech industries, serving clients who require precise and reliable methods for analyzing complex biological substances.
The company's main offerings include Proteomix® HIC Butyl columns and Monomix™ MC SEC resins. The Proteomix® HIC Butyl columns are used for high-resolution hydrophobic interaction separation of biomolecules, such as monoclonal antibodies (mAb), Antibody Drug Conjugates (ADCs), and their fragments. Simply put, these columns help to separate complex biological substances based on their hydrophobicity, or their tendency to repel water.
The Monomix™ MC SEC resins, on the other hand, are used for size exclusion chromatography (SEC), a method used to separate biomolecules based on their size. These resins are particularly stable and versatile, with a broad pH tolerance range and compatibility with many commonly used solvents and buffers.
Sepax Technologies also offers a full chromatographic separation solution for ADCs, which includes a range of products for the analysis of ADCs aggregate, monomer, fragment, and free drug. This comprehensive solution allows for detailed analysis of ADCs, which are complex molecules used in targeted cancer therapies.
The company's business model is based on selling these high-tech products and solutions to clients in the biotech and pharmaceutical industries. They also offer technical support to their clients, ensuring that their products are used effectively and efficiently.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- Newark, United States
- Employees
- 87
- Open positions
- 1
- Dealroom signal
- 38.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Tech for Biotech and Pharma, Biotech and Pharma, Hard Tech, Resin, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Nov 2021 | $69M | $275M | CITIC PE · Sinovac Biotech · Gan & Lee Pharmaceutical · Sherpa Venture Partners | ↗ |
| SERIES COther financing | Mar 2021 | $28M | $110M | China Life Healthcare Fund · Fosun Capital | ↗ |
Growth signals
Latest recorded traffic for Sepax-tech is 5.3K monthly website visits, up 29.3% over the last three months. Sepax-tech's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- CCComway Capital
Huatai Zijin Investment- SMSuzhou Dunhang Investment Management
Series B and later8 investors entered at this stage
China Life Healthcare Fund- FCFosun Capital
CITIC PE
Sinovac Biotech
Gan & Lee Pharmaceutical
Sherpa Venture Partners
GL Ventures- SCSinopharm Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sepax-tech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sepax-tech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







